Zacks Research Cuts Earnings Estimates for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research decreased their Q3 2025 earnings estimates for shares of Zimmer Biomet in a research note issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $1.95 for the quarter, down from their prior forecast of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

Several other research analysts have also recently issued reports on ZBH. UBS Group decreased their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a report on Thursday, August 8th. Evercore ISI lowered their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. TD Cowen lowered their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a report on Friday, September 6th. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Raymond James lowered their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Trading Down 0.3 %

Shares of NYSE ZBH opened at $110.64 on Wednesday. Zimmer Biomet has a 1 year low of $101.47 and a 1 year high of $133.90. The stock has a market cap of $22.03 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02. The firm has a 50-day moving average of $106.95 and a 200 day moving average of $109.47. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter last year, the firm earned $1.65 EPS. The company’s revenue was up 4.1% on a year-over-year basis.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date was Monday, September 30th. Zimmer Biomet’s payout ratio is 18.25%.

Institutional Trading of Zimmer Biomet

Hedge funds have recently modified their holdings of the company. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $28,000. Bangor Savings Bank purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $31,000. Family Firm Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $33,000. Finally, Brooklyn Investment Group acquired a new position in Zimmer Biomet in the 3rd quarter worth approximately $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.